Biotech Briefing: Advancing Biotechs Forging Ahead With Breaking News Developments: Alliqua, OncoMed Pharmaceuticals,

    Biotech Briefing: Advancing Biotechs Forging Ahead With Breaking News
Developments: Alliqua, OncoMed Pharmaceuticals, EnteroMedics, Unilife, Amarin

PR Newswire

CORAL SPRINGS, Florida, December 4, 2013

CORAL SPRINGS, Florida, December 4, 2013 /PRNewswire/ --

Biotechs develop new products and making an impact in the healthcare sector:
Alliqua. Inc. (OTCQB: ALQAD), OncoMed Pharmaceuticals, Inc. (NASDAQ: OMED),
EnteroMedics Inc. (NASDAQ: ETRM), Unilife Corporation (NASDAQ: UNIS) and
Amarin Corporation plc (NASDAQ: AMRN) 

Alliqua, Inc. (OTCQB:ALQAD) has appointed Perry A. Karsen to its Board of
Directors, increasing the size of the Board to nine members. Mr. Karsen, age
58, is Chief Executive Officer of Celgene Cellular Therapeutics, a wholly
owned subsidiary of Celgene Corporation, for which Mr. Karsen also serves as
Executive Vice President and Chief Operations Officer.

To read the full press release, please click

Mr. Karsen said, "Last month, I was pleased to help oversee the licensing of
advanced wound care products, Biovance^® and Extracellular Matrix (ECM), from
Celgene Cellular Therapeutics to Alliqua. I am impressed by Alliqua's existing
suite of wound care products and I look forward to working with Alliqua's
management as Alliqua expands its sales, marketing and distribution

OncoMed Pharmaceuticals, Inc. (NASDAQ: OMED) and Celgene Corporation (NASDAQ:
CELG) recently announced an agreement to jointly develop and commercialize up
to six anti-cancer stem cell (CSC) product candidates from OncoMed's biologics
pipeline, including demcizumab (OMP-21M18, Anti-DLL4). OncoMed will control
and conduct initial clinical studies at which point Celgene has an option to
license worldwide rights to up to six novel anti-CSC therapeutic candidates.
OncoMed retains global co-development and U.S. co-commercialization rights for
five of the six anti-CSC product candidates with 50/50 U.S. profit sharing,
and royalties to be received in other territories. Celgene will also have
research, development and commercialization rights to small molecule compounds
in an undisclosed cancer stem cell pathway. 

EnteroMedics Inc. (NASDAQ: ETRM) the developer of medical devices using
neuroblocking technology to treat obesity, metabolic diseases and other
gastrointestinal disorders, has announced 18 month efficacy and safety results
from its 5 year ReCharge Pivotal Trial of VBLOC^®vagal blocking therapy for
the treatment of obesity. Patients in the VBLOC group (n=117),achieved
excess weight loss (EWL) of 25%, or 10% total body weight loss (TBL), compared
to 12% EWL, or 4% TBL for sham control group patients (n=42).The 13%
difference in EWL demonstrated statistical superiority over sham control (p <
0.001). In total, 54% of patients in the VBLOC group achieved at least 20% EWL
and 41% achieved at least 25% EWL, compared to 26% and 17%, respectively, for
the sham control group at the 18-month interval.Significantly, approximately
78% of the patients who reported for their 18-month visit remained under the
clinical trial's randomized blind. 

Unilife Corporation (NASDAQ: UNIS) recently announced an agreement with
Novartis to supply clinical products from one of its platforms of injectable
drug delivery systems for use with one of Novartis' targeted early-stage
pipeline drugs. Under this agreement, Unilife will supply Novartis with a
customized delivery device, consisting of syringe, needle, tubing, controller
and pump, to enable administration of a novel investigational Novartis drug
into a targeted organ in clinical trials. Unilife has granted Novartis an
option for exclusivity under this agreement. The program to supply customized
products for clinical use with Novartis drug candidates is the next phase in a
development collaboration between the parties that was commenced in 2011, and
continues to progress successfully. Under this agreement Unilife will generate
revenue on the basis of the clinical product supplies and activities involved
in clinical development. 

Amarin Corporation plc (NASDAQ: AMRN) a biopharmaceutical company focused on
the commercialization and development of therapeutics to improve
cardiovascular health, announced today that the United States Patent and
Trademark Office (USPTO) has published notification of a Notices of Allowance
for Amarin's U.S. Patent Applications Serial Numbers 13/685,281, and
13/685,291, each titled "Stable Pharmaceutical Composition and Methods of
Using Same." The claims in these allowed applications cover methods of
lowering triglycerides by administering a pharmaceutical composition comprised
of a mixture of free fatty acids, including EPA and/or DHA to varying degrees,
to patients with severe hypertriglyceridemia (the MARINE population) and in
patients with hypertriglyceridemia on concomitant statin therapy (the ANCHOR
population). A Notice of Allowance is issued after the USPTO makes a
determination that a patent can be granted from an application. The issued
patents would have terms that expire no earlier than in 2030. is leading provider of third party publishing &news
dissemination services. If you would like more information regarding our news
coverage solutions, please visit for more
details. Get an edge on the market with ourPremium News Alerts that are
FREE for a limited time at Follow us on
Facebook: and
Twitter: Sign up for our FREE SMS News alerts
delivered directly to your mobile phone by texting the word PRESS to
545454.(SMS alerts are free, however data rates may apply, check your
wireless plan for details.)

DISCLAIMER: FN Media Group LLC (FNMG) is a third party publisher and news
dissemination service provider, which disseminates electronic information
through multiple online media channels. FNMG is NOT affiliated in any manner
with any company mentioned herein. FNMG and its affiliated companies are a
news dissemination and financial marketing solutions provider and are NOT a
registered broker/dealer/analyst/adviser, holds no investment licenses and may
NOT sell, offer to sell or offer to buy any security. FNMG's market updates,
news alerts and corporate profiles are NOT a solicitation or recommendation to
buy, sell or hold securities. The material in this release is intended to be
strictly informational and is NEVER to be construed or interpreted as research
material. All readers are strongly urged to perform research and due
diligence on their own and consult a licensed financial professional before
considering any level of investing in stocks. The companies that are
discussed in this release may or may not have approved the statements made in
this release. FNMG is not liable for any investment decisions by its readers
or subscribers. Investors are cautioned that they may lose all or a portion
of their investment when investing in stocks. FNMG was compensated one
thousand two hundred fifty dollars for the dissemination of the news released
by Alliqua, Inc. by the company.


This release contains "forward-looking statements" within the meaning of
Section 27A of the Securities Act of 1933, as amended, and Section 21E the
Securities Exchange Act of 1934, as amended and such forward-looking
statements are made pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. "Forward-looking statements"
describe future expectations, plans, results, or strategies and are generally
preceded by words such as "may", "future", "plan" or "planned", "will" or
"should", "expected," "anticipates", "draft", "eventually" or "projected". You
are cautioned that such statements are subject to a multitude of risks and
uncertainties that could cause future circumstances, events, or results to
differ materially from those projected in the forward-looking statements,
including the risks that actual results may differ materially from those
projected in the forward-looking statements as a result of various factors,
and other risks identified in a company's annual report on Form 10-K or 10-KSB
and other filings made by such company with the Securities and Exchange
Commission. You should consider these factors in evaluating the
forward-looking statements included herein, and not place undue reliance on
such statements. The forward-looking statements in this release are made as of
the date hereof and FNMG undertakes no obligation to update such statements.

Contact Information:
Company: FN Media Group, LLC
Contact email:
U.S. Phone: +1(954)345-0611

SOURCE FN Media Group, LLC
Press spacebar to pause and continue. Press esc to stop.